Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2062-2066

  Lodise, T P ^a,b   Butterfield, J M ^a   Hegde, S S ^c   Samara, E ^d   Barriere, S L ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c THERAVANCE INC   (United States)

^d PharmaPolaris International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; TELAVANCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN INFECTION; SKIN STRUCTURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; AREA UNDER CURVE; BODY WEIGHT; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CREATININE; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, STATISTICAL; MONTE CARLO METHOD; POPULATION; PROBABILITY; SKIN DISEASES, INFECTIOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858682584     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00383-11     Document Type: Article

References (21)

1. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. 2010. Pharmacokinetic- pharmacodynamic considerations in the design of hospitalacquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin. Infect. Dis. 51(Suppl. 1):S103-S110.
2. Ambrose PG, et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86. (Pubitemid 44968990)
3. Astellas Pharma US, Inc, Theravance, Inc. 2009. Vibativ (telavancin) for injection: prescribing information. Astellas Pharma US, Inc, Deerfield, IL, and Theravance, Inc, South San Francisco, CA.
4. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. 2010. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy 30:35-42.
6. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. 2010. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy 30:806-811.
7. Gotfried MH, et al. 2008. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob. Agents Chemother. 52:92-97.
8. Hegde SS, et al. 2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob. Agents Chemother. 48:3043-3050. (Pubitemid 38989173)
9. Lodise TP, Jr, et al. 2007. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob. Agents Chemother. 51:2378-2387.
10. Lodise TP, Patel N, Hedge S, Shaw J, Barriere S. April 2010. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections with varying degrees of renal function, abstr 468. 20th Eur. Congr. Clin. Microbiol. Infect. Dis., Vienna, Austria.
11. Lodise TP, et al. April 2010. Mouse thigh MRSA infection model data and mathematical modelling to determine telavancin dosing for complicated skin and skin structure infection trials, abstr 469. 20th Eur. Congr. Clin. Microbiol. Infect. Dis., Vienna, Austria.
12. Patel N, Scheetz MH, Drusano GL, Lodise TP. 2010. Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success. J. Antimicrob. Chemother. 65:2285-2290.
13. Patel N, Scheetz MH, Drusano GL, Lodise TP. 2010. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob. Agents Chemother. 54:460-465.
14. Samara E, Shaw J-P, Barriere SL, Wong SL, Worboys P. 2012. Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob. Agents. Chemother. 56:2067-2073.
15. Shaw JP, et al. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49:195-201. (Pubitemid 40065793)
16. Stryjewski ME, et al. 2006. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50:862-867. (Pubitemid 43327787)
17. Stryjewski ME, et al. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by grampositive organisms. Clin. Infect. Dis. 46:1683-1693. (Pubitemid 351706765)
18. Stryjewski ME, et al. 2005. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin. Infect. Dis. 40:1601-1607. (Pubitemid 40720810)
19. Sun HK, et al. 2006. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother. 50: 788-790. (Pubitemid 43191003)
20. Wong SL. 25 September 2006. Pharmacokinetics of intravenous telavancin in normal subjects and subjects [with] various degrees of renal dysfunction. Theravance study 103a-PK. Theravance, Inc, South San Francisco, CA.
21. Wong SL, Barriere SL, Kitt MM, Goldberg MR. 2008. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J. Antimicrob. Chemother. 62:780-783.